The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy
Cancer Drug Resistance · 03.07.2025
DOI: 10.20517/cdr.2025.49 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 03.07.2025. Verfasst von Meijiang Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Immunology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Antibody-Drug Conjugates (ADCs) have achieved significant success in cancer therapy by combining the targeting specificity of monoclonal antibodies with cytotoxic payloads. However, the concomitant issue of drug resistance has become increasingly prominent, with primary mechanisms including alterations in target antigen expression, impaired drug transport, and inhibition of cell death pathways. ADCs have also shown emerging therapeutic potential in the treatment of autoimmune diseases; for instance, ABBV-3373 has achieved initial success in this area, yet it also faces unique challenges such as the safety of long-term administration, immunogenicity, and heterogeneity of target cells. Addressing these challenges requires multidimensional innovations, including optimizing molecular design, exploring combination therapy strategies, and introducing artificial intelligence (AI)-assisted development. These efforts aim to transition ADCs from the traditional “targeted killing” paradigm to intelligent and personalized precision delivery systems, thereby offering more therapeutic options for patients with cancer and autoimmune diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology and Immunology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.
- Sinopharm Dongfeng General Hospital (Hubei Clinical Research Center of Hypertension), Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan 442000, Hubei, China.
- Department of Rheumatology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian, China.
- Fujian Institute of Clinical Immunology, Fuzhou 350001, Fujian, China.
- Department of Immunology, School of Medicine, Yangtze University, Jingzhou 434023, Hubei, China.
- Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Zitieren
APA
Zhou, M., Huang, Z., Ma, Z., Chen, J., Lin, S., Yang, X., Gong, Q., Braunstein, Z., Wei, Y., Rao, X., & Zhong, J. (2025). The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.49
Vancouver
Zhou M, Huang Z, Ma Z, Chen J, Lin S, Yang X, et al. The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy. Cancer Drug Resistance. 2025. doi:10.20517/cdr.2025.49
BibTeX
@article{Zhou2025,
author = {Zhou, Meijiang and Huang, Zhiwen and Ma, Zijun and Chen, Jun and Lin, Shunping and Yang, Xuwei and Gong, Quan and Braunstein, Zachary and Wei, Yingying and Rao, Xiaoquan and Zhong, Jixin},
title = {The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy},
journal = {Cancer Drug Resistance},
year = {2025},
doi = {10.20517/cdr.2025.49}
}
EUVIMED